Medicines and disease areas 

Astellas has reached more than 172 million patients in 103 locations around the world with our products. Our on-market portfolio includes transformative therapies in oncology, ophthalmology, urology, immunology and women's health.

Two women embrace, expressing Astellas’ commitment to therapies that have transformed the lives of millions of patients.

Main products

The products listed on this website are Astellas' main products globally. Availability may vary by location or region, and products may be marketed under different brand names, indications, dosages and strength. These medications are typically available only by prescription from healthcare professionals.

Japan product information and related documents can be accessed here: Medicines available in Japan

Product information and related documents for all other locations can be accessed here: Medicines by Location

PADCEV™

enfortumab vedotin

For the treatment of locally advanced or metastatic urothelial cancer

IZERVAY™

avacincaptad pegol intravitreal solution

For the treatment of geographic atrophy secondary to age-related macular degeneration 

VEOZA™/VEOZAH™

fezolinetant

For the treatment of moderate to severe vasomotor symptoms associated with/due to menopause

VYLOY™

zolbetuximab

For the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive

XOSPATA™

gilteritinib

For the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation 

XTANDI™

enzalutamide

For the treatment of advanced prostate cancer, including metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence (BCR)

 

BETANIS™/MYRBETRIQ™/
BETMIGA™

mirabegron

For the treatment of overactive bladder (OAB) 

PROGRAF™/PROGRAF XL™/ ADVAGRAF™/ASTAGRAF XL™/ Graceptor™/MODIGRAF™

tacrolimus

For use with other adjuvants and medicines to help prevent organ rejection in people who have had a kidney, liver, heart or lung transplant

Disease areas

Our current product portfolio supports a diverse range of therapeutic areas including oncology, ophthalmology, urology, immunology and women's health.

Oncology

At Astellas, we are pioneering science to deliver the oncology medicines of tomorrow, targeting some of the most challenging cancers with a sense of urgency and an unwavering determination to bring innovative medicines to the people who need them.

Ophthalmology

We have made a long-term commitment to people with vision loss: to help build a brighter future in which retinal diseases that cause blindness are treatable, and ultimately preventable.

Urology

With over 30 years of experience in urology, we are passionate about transforming the lives of people affected by overactive bladder (OAB) and deeply understand the daily challenges patients face.

Immunology of transplantation

We are dedicated to providing transplant specialists with evidence-based solutions that optimize care and drive positive outcomes at every stage of the transplant journey.

Women's health

We recognize that women’s health, particularly menopause, is an area that has been underserved for too long and we are committed to delivering medical innovation that will improve menopause care for the millions of people experiencing it.

Keep exploring

A scientist studies samples under a microscope, advancing Astellas' R&D for innovative, patient-centered therapies.

Research and development

Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more about our R&D approach. 

A patient surrounded by loved ones shows Astellas’ focus on improving quality of life with real-world treatment impact.

Patient centricity

We support the development of innovative health solutions through a deep understanding of the patient experience, real-world evidence, medical needs and behavioral drivers of care. Learn more about how we are mobilizing teams across Astellas to improve patient outcomes.

A group of healthcare professionals in discussion, highlighting Astellas’ commitment to collaborative, patient-focused care.

Healthcare professionals

We invite healthcare professionals to visit our HCP portal, where you will find valuable information and resources that reflect our commitment to collaboration and addressing unmet medical needs.